Skip to main content

Monte Rosa Therapeutics (NYSE: GLUE) — Company Overview, News & Financial Data

Monte Rosa Therapeutics logo
GLUE Monte Rosa Therapeutics
Monte Rosa Therapeutics primary media
Company profile

Monte Rosa Therapeutics

About

Explore United States companies

Monte Rosa Therapeutics (NASDAQ:GLUE) is dedicated to advancing the field of molecular degradation to develop innovative therapies for patients with diseases previously thought undruggable. Specializing in using small molecules to degrade disease-causing proteins, the company is at the forefront of creating a pipeline of projects aimed at a range of diseases, including cancer. Monte Rosa is driven by its objective to harness the power of its proprietary platform to bring life-changing treatments to those in urgent need, continually pushing the boundaries of what is possible in targeted therapy.

Snapshot

Public USOwnership
2019Year founded
133Employees
Boston, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Boston, US

Products and/or services of Monte Rosa Therapeutics

  • Development of molecular glue degraders designed to eliminate undruggable proteins associated with various cancers.
  • Research in targeted protein degradation using small molecules to modulate protein levels for therapeutic purposes.
  • Creation of a proprietary platform, QuEEN, for the discovery and development of novel E3 ligases.
  • Partnerships with pharmaceutical companies to advance the development and commercialization of targeted therapies.
  • Investment in precision medicine initiatives to tailor treatments to individual genetic profiles, improving efficacy and reducing side effects.
  • Engagement in various oncology-focused clinical trials to validate the effectiveness of novel therapeutic approaches.

Monte Rosa Therapeutics executive team

  • Markus WarmuthPresident, CEO & Director
  • Philip NicksonChief Business & Legal Officer
  • Filip JankuChief Medical Officer
  • Matthew BowenCorporate Controller & Principal Accounting Officer
  • Jennifer ChampouxChief Operating Officer
  • Magnus WalterChief Technology Officer
  • John C. CastleChief Data & Information Officer
  • Sharon TownsonChief Scientific Officer
  • Andrew FunderburkChief Investor Relations and Strategy Officer